# ACCO Brands: cheap on earnings, thin on equity ACCO, NYSE. Published October 13, 2026. Price as of the October 12, 2026 regular session close. ## Verdict: HOLD at $4.54 ACCO trades at 5.1 times 2026 adjusted earnings with a 6.6% dividend yield, but $802 million of net debt ranks ahead of a $434 million equity value. My Base value is $4.94, 8.8% above the price, which is not enough cushion for that much leverage. Hold, watchlist for new money. The buy zone starts at $2.72. - Bear value: $1.93 - Base value: $4.94 - Bull value: $8.36 - Upside to base value: +8.8% - Maximum buy price: $2.72 - Required margin of safety: 45% - Net debt per $1 of equity value: $1.85 - Value of one turn of EBITDA multiple: $1.85 a share, 41% of the price - Business quality: 38/100 - Valuation score: 32/100 - Confidence: 13/25, grade C Screens love ACCO. At $4.54 it trades at 5.1 times the middle of its 2026 adjusted earnings guidance and pays $0.30 a year, a 6.6% yield. Then comes the balance sheet. Net debt averages $802 million across the last two balance dates, against a market value of $434 million, so every dollar of equity sits on top of $1.85 of debt. At that gearing one turn of EBITDA multiple moves the share price by $1.85, which is 41% of what you pay today. At the October 12, 2026 regular session close of $4.54 the shares trade 8.1% below my triangulated Base value of $4.94, an upside of 8.8%. The Bear value of $1.93 is 57.4% below the price and the Bull value of $8.36 is 84.0% above it. Confidence is grade C (13/25), the required margin of safety (MOS) is 45%, and the maximum buy price is **$2.72**. The U.S. market was still open when I wrote this, so the October 13 close is not used. Valuation route: branded consumer, office and technology products maker with heavy debt. Primary method: enterprise value (EV, equity plus net debt) against normalized EBITDA after stock pay, then net debt subtracted to reach the share value. Secondary method: price against normalized free cash flow, which is after interest and restructuring. Classification: Standard (1/12). Values are present fair value estimates, not 12 month price targets. ## What ACCO is ACCO Brands is a Lake Zurich, Illinois maker of school, office and technology accessories. The names you may know: Swingline, Five Star, Mead, Leitz, GBC, Quartet, AT-A-GLANCE and Kensington, plus PowerA gaming accessories. About 75% of 2025 sales came from brands ranked first or second in their categories, and the twelve biggest brands produced about $1.1 billion. The Americas make up 59% of sales and International 41%. About 40% of products come from ACCO's own plants and 60% from suppliers, mostly in Asia, which is why tariffs matter: the 10-K says U.S. tariffs, especially on goods from China and Vietnam, have had a material adverse effect. The business shrinks in a steady way. Net sales fell from $1,947.6 million in 2022 to $1,524.7 million in 2025, down 21.7%, and comparable sales dropped 9.3% in 2025 alone. Management says enterprise buyers are postponing technology accessory deals because AI budgets come first. What keeps profit alive is cost: a $100 million multi-year savings program that management expects to deliver in full this year. In January 2026 ACCO bought EPOS, a business audio and video products company, from Demant A/S for a net $1.1 million after cash acquired. Management expects about $80 million of EPOS sales this year and $15 million of cost savings within 18 months. It also says EPOS will be neutral to adjusted earnings per share in 2026, which is a polite way of saying the $36.5 million accounting gain from buying it so cheaply is not the same as profit. ## The latest quarter and half year | Second quarter and first half 2026 | Result | | --- | --- | | Q2 net sales | $415.1 million, up 5.1% (comparable sales down 2.3%; EPOS added 5.7 points, currency 1.7) | | Q2 adjusted gross margin | 33.1%, up 0.2 points on cost savings | | Q2 adjusted operating income | $48.1 million, 11.6% margin (Q2 2025: $47.1 million, 11.9%) | | Q2 adjusted EPS / GAAP EPS | $0.29 (from $0.28) / $0.15 (from $0.31) | | H1 net sales | $758.8 million, up 6.5% (comparable sales down 2.5%) | | H1 adjusted EPS / GAAP EPS | $0.31 (from $0.25) / $0.35 (from $0.17) | | H1 net income (GAAP) | $33.5 million, including a $36.5 million bargain purchase gain on EPOS | | H1 free cash flow | -$38.6 million (H1 2025: -$40.2 million), the normal seasonal outflow | | Net debt, June 30 / leverage | $827.4 million (a year earlier $854.0 million) / 4.3 times adjusted EBITDA | | Segments, Q2 adjusted operating income | Americas $55.8 million (from $43.2 million), International $3.6 million (from $12.4 million) | | 2026 guidance | Sales up 2% to 5%, adjusted EPS $0.87 to $0.91, free cash flow $75 million to $85 million, year end leverage 3.7 to 3.9 times | | Q3 guidance | Sales down 1% to up 2%, adjusted EPS $0.17 to $0.21. Third quarter results are expected on October 29, 2026. | Look at what changed underneath. Americas adjusted operating margin jumped to about 21.2% from 17.4%, on the cost program, and management now expects back-to-school sales to be up mid single digits for the season. International went the other way: comparable sales fell about 9%, demand in Europe, the Middle East, Africa and Australia was soft, and a distribution system upgrade at the largest European distribution center disrupted deliveries. Adjusted operating income there fell to $3.6 million from $12.4 million. Management said June improved. The second half carries a warning. Management expects lower gross profit and operating margins than last year because inflation in costs runs ahead of price increases. The raised earnings guidance reflects a stronger first half, not a better second half. ## Cash flow, debt and the covenant ACCO uses cash in the first half and makes it back in the second. In 2025 free cash flow (operating cash flow minus capital spending) was $50.8 million, down from $132.3 million in 2024. For 2026 management guides $75 million to $85 million, after about $24 million of restructuring payments and $15 million of capital spending. That guidance is the most important number here: it is the cash the business keeps after interest, and it decides how fast the debt falls. | Debt at June 30, 2026 | Amount ($ million) | Rate | Due | | --- | --- | --- | --- | | Euro term loan A | 95.0 | 4.54% | October 2029 | | Euro revolver | 110.8 | 4.54% | October 2029 | | U.S. dollar revolver | 113.6 | 6.05% | October 2029 | | Australian dollar revolver | 27.2 | 6.72% | October 2029 | | Senior unsecured notes | 575.0 | 4.25% | March 2029 | | Other borrowings | 12.2 | | | | Total debt (cash $106.4 million, net debt $827.4 million) | 933.8 | | | Nothing is due until 2029, and $204.8 million is available under the revolver. The pressure points are different. The credit agreement allows a leverage ratio (net debt divided by trailing twelve month adjusted EBITDA) of at most 4.75 times for the first two quarters of 2026 and 4.25 times for the third and fourth. The ratio was 4.3 times at June 30, the seasonal peak. Management guides to 3.7 to 3.9 times at year end, and the third quarter normally brings in cash from back-to-school, so I treat this as a watch item rather than a forecast of trouble. The 2025 amendment also caps 2026 dividends plus buybacks at the greater of $40 million or 1% of total assets. The larger test is later. The $575 million of 4.25% notes come due in March 2029 and, according to the 10-Q, must be refinanced by September 2028. At an assumed 8.5% (my estimate, not a quote) the extra interest is about $24 million a year, or $0.19 a share after tax. That is 21% of 2026 adjusted earnings per share. I do not put it in the Base, because the date is two years away and the multiples already carry a risk discount, but it is in the stress tests below. ## Which earnings to value | Year | Net sales ($ million) | Adjusted EPS | Adjusted EBITDA ($ million) | Free cash flow ($ million) | | --- | --- | --- | --- | --- | | 2022 | 1,947.6 | $1.04 | 227.7 | 61.1 | | 2023 | 1,832.8 | $1.09 | 250.5 | 114.9 | | 2024 | 1,666.2 | $1.02 | 228.3 | 132.3 | | 2025 | 1,524.7 | $0.84 | 188.9 | 50.8 | | 2026 guidance and my estimate | up 2% to 5% | $0.87 to $0.91 | 191.1 (my estimate) | 75 to 85 | ACCO's adjusted EBITDA adds back stock-based pay and restructuring, according to the reconciliation in its 2025 results. Stock pay was $11.5 million in 2025 and $7.2 million in the first half of 2026, so I subtract it. Restructuring is a different case: $21.6 million in 2025, $16.8 million in 2024 and about $24 million of cash in 2026. A cost cut that is repeated every year is a cost, so I keep it out of the EBITDA multiple but inside the free cash flow method, and I test the harsher view below. My 2026 estimate works like this. First half adjusted EBITDA was $76.7 million. The guidance implies a flat second half ($0.58 of adjusted earnings per share against $0.59 last year), so I hold the second half at the 2025 level of $114.4 million, for $191.1 million. After about $14.4 million of stock pay (the first half doubled) that is **$176.7 million**. For 2025 the same calculation gives $177.4 million. The Base uses **$177 million**, which is 11.4% of $1,550 million of normalized sales. Diluted shares of 95.6 million are about 3.6% above the 92.3 million outstanding on July 24, 2026, so diluted shares are used throughout. ## Primary valuation: EV to EBITDA For a levered manufacturer the cleanest question is what the whole business is worth, then how much of that belongs to the owners after the lenders. I use net debt of **$802.0 million**, the average of $776.5 million at December 31, 2025 and $827.4 million at June 30, 2026, because ACCO borrows in the first half and repays in the second. Using either end alone moves the answer by about 3%. The multiple is 7.0 times in the Base. My framework puts struggling or commodity-like businesses with falling sales at 5 to 8 times and stable, branded ones at 8 to 12 times. ACCO has leading brands and a working cost program, but sales are down 22% in three years, debt is 4.3 times EBITDA and the moat does not look wide. That puts it in the upper half of the lower band. I could not verify a peer table or ACCO's own multiple history on the same basis, so the multiple is an assumption and is tested at 6 and 8 times. | | Bear | Base | Bull | | --- | --- | --- | --- | | Normalized EBITDA after stock pay ($ million) | 155.0 | 177.0 | 200.0 | | Multiple of EBITDA | 6.0x | 7.0x | 8.0x | | Enterprise value ($ million) | 930.0 | 1,239.0 | 1,600.0 | | Less net debt ($ million) | 802.0 | 802.0 | 802.0 | | Equity value ($ million) | 128.0 | 437.0 | 798.0 | | Value per diluted share (95.6 million) | $1.34 | $4.57 | $8.35 | ### Sensitivity: value per share (EV to EBITDA method only) | EBITDA after stock pay \ multiple | 6.0x | 6.5x | 7.0x | 7.5x | 8.0x | | --- | --- | --- | --- | --- | --- | | $150M | $1.03 | $1.81 | $2.59 | $3.38 | $4.16 | | $165M | $1.97 | $2.83 | $3.69 | $4.56 | $5.42 | | $177M | $2.72 | $3.65 | $4.57 | $5.50 | $6.42 | | $190M | $3.54 | $4.53 | $5.52 | $6.52 | $7.51 | | $205M | $4.48 | $5.55 | $6.62 | $7.69 | $8.77 | The grid shows the real argument. Between $165 million and $190 million of EBITDA and 6.5 to 7.5 times, the value runs from $2.83 to $6.52. The price of $4.54 sits near the middle, and the dividend is not what decides the outcome. ## Secondary valuation: free cash flow The second method asks what the shareholders keep after interest, restructuring and capital spending. I normalize free cash flow at **$75 million**, the low end of 2026 guidance. The five year average from 2022 to 2026 is $87.8 million, but it mixes a $132.3 million peak with a $50.8 million trough, so I do not use it. That is $0.785 per diluted share. My framework gives cyclical, indebted businesses 8 to 10 times and takes off 1 to 2 turns for rising debt, falling returns and dilution above 2%. ACCO shows falling returns and dilution, and net debt ended 2025 above the 2024 level: shares outstanding rose from 90.17 million on March 2 to 92.31 million on July 24, 2026, up 2.4% in under five months. I use 7.0 times. | | Bear | Base | Bull | | --- | --- | --- | --- | | Normalized free cash flow ($ million) | 45 | 75 | 100 | | Free cash flow per diluted share | $0.471 | $0.785 | $1.046 | | Multiple of free cash flow | 6.0x | 7.0x | 8.0x | | Value per share | $2.82 | $5.49 | $8.37 | Seven times free cash flow, with that debt, implies about 7.5 times EBITDA. That is a little richer than the primary method, which is why the two Base values are not identical. ## History and growth diagnostics I could not build a reliable valuation history for ACCO on this basis, so I use none. What I can say: the shares closed near the top of a 52 week range of $2.81 to $4.56, and over five years to the end of 2025 the stock returned $57.65 per $100 invested, against $134.40 for the Russell 2000, according to the 10-K. The growth-adjusted check (PEG) is a diagnostic only. The price is 5.1 times 2026 adjusted earnings per share of $0.89 and 7.3 times trailing GAAP earnings of $0.62. Adjusted earnings per share are up about 6% from 2025 but 18% below 2023's $1.09, so a PEG ratio is not meaningful. Growth durability: uncertain. Cyclical distortion: low, because the decline in sales is structural, not a cycle. Free cash flow growth quality needs the same care. From $61.1 million in 2022 to the $80 million midpoint of 2026 guidance is a 7.0% annual rate, and 6.9% per share, but 2022 was a low starting year and 2024 reached $132.3 million. This is a recovery inside a shrinking business, not growth. Forward free cash flow yield on the $80 million midpoint is 18.4% of the $434 million market value, trailing twelve month yield is 12.1% ($52.4 million, my calculation). My estimate reliability is medium. The stress test on the free cash flow method: | Free cash flow stress (7.0x) | Free cash flow | Value per share | | --- | --- | --- | | Normalized Base | $75 million | $5.49 | | 20% lower | $60 million | $4.39 | | 40% lower | $45 million | $3.29 | ## Valuation triangulation | Method | Bear | Base | Bull | Weight | | --- | --- | --- | --- | --- | | Enterprise value to EBITDA | $1.34 | $4.57 | $8.35 | 60% | | Price to free cash flow | $2.82 | $5.49 | $8.37 | 40% | | Triangulated value | $1.93 | $4.94 | $8.36 | 100% | The two Base values differ by 18.3% measured against their midpoint, inside my 20% comfort band but close to it. I weight the EBITDA method 60% because it is the one that is independent of how ACCO happens to be financed. The same weights apply in all three scenarios, so the 40% free cash flow weight is explicit and not an average by default. ## What is the market already pricing in? At $4.54 and 95.6 million diluted shares the market value is **$434.0 million** and the enterprise value is $1,236.0 million, which is 6.98 times my Base EBITDA. Put the other way around, a 7.0 times multiple needs EBITDA of only $176.6 million, almost exactly what I expect for 2026. On free cash flow the price is 5.8 times my $75 million, a 17.3% yield. The market is not betting on a rescue. It prices in earnings that stop falling, and that is where the downside sits if they do not. ## Bear, base and bull scenarios | | Bear | Base | Bull | | --- | --- | --- | --- | | Probability | 25% | 50% | 25% | | Net sales | $1,450 million, down 5% | $1,550 million | $1,600 million, up 5% | | EBITDA margin after stock pay | 10.7% | 11.4% | 12.5% | | Normalized EBITDA after stock pay | $155 million | $177 million | $200 million | | Multiple of EBITDA / free cash flow | 6.0x / 6.0x | 7.0x / 7.0x | 8.0x / 8.0x | | EBITDA method / free cash flow method | $1.34 / $2.82 | $4.57 / $5.49 | $8.35 / $8.37 | | Triangulated value | $1.93 | $4.94 | $8.36 | | Versus $4.54 | -57.4% | +8.8% | +84.1% | **Bear:** sales fall another 5%, tariffs and input costs outrun price increases (management already says pricing lags in the second half) and the margin slips to 10.7%. At 6 times, enterprise value of $930 million leaves only $128 million for the equity, 14% of the enterprise value. **Base:** sales settle near $1,550 million, a little under the 2026 guidance midpoint of about $1,578 million, and margin holds at 2025 levels. **Bull:** the cost program and $15 million of EPOS savings carry the margin back toward the 13.0% of 2024, back-to-school is up mid single digits and sales return to growth. The probability-weighted value is **$5.04**, 11.1% above the price. The skew looks generous on paper, 84% up against 57% down, but the Bear is not a disaster case. It is the same business with 10% less EBITDA and one turn less multiple. ## How the buy price is set A Confidence C score carries a base margin of safety of 35%. I add 5 points for leverage (4.3 times EBITDA at June 30 and a covenant that tightens) and 5 points for a structurally shrinking top line. No negative modifier applies. The required MOS is **45%**, and the maximum buy price is $4.94 times 0.55, or **$2.72**. That is 40% below the current price and above the Bear value of $1.93. At $2.72 the equity would be worth about $260 million, and the debt would be 3.1 times the equity, which is still a lot. ## Dividend ACCO pays $0.075 a quarter, or $0.30 a year, a 6.6% yield at $4.54. The annual rate has been $0.30 in every year from 2022 to 2025. Dividends cost $27.0 million in 2025 and $13.8 million in the first half of 2026, about a third of the $80 million free cash flow midpoint. The 10-K says debt reduction comes first in capital allocation, and there were no buybacks in the first half of 2026 after $15.1 million a year earlier. A dividend at that cost is covered, but the covenant cap on dividends and buybacks (the greater of $40 million or 1% of total assets in 2026) tells you where the lenders would draw the line. Dividends paid to non-U.S. holders face U.S. withholding tax, and the rate depends on your tax treaty and your broker. ## Reasons to own ACCO - **The price already assumes stable earnings.** Seven times my Base EBITDA, and 5.8 times free cash flow, leaves little room for hope to be priced in. - **Cash arrives in the second half.** Guidance of $75 million to $85 million of free cash flow is 17% to 20% of the equity value, and every $80 million of debt paid down adds about 18% to the equity. - **The cost program is working where it matters.** Americas adjusted operating margin reached 21.2% in the second quarter, and management raised sales and earnings guidance in July. - **EPOS was bought for almost nothing.** A net $1.1 million, about $80 million of sales and a $15 million synergy target, paid in cash. - **Tariff refunds are not in the numbers.** The company filed $20 million of claims expected in 2026 and $5 million in 2027, and it books them only when receipt is assured. In my test they add about $0.12 a share. ## What could go wrong? - **Thesis breaker: leverage does not come down.** The ratio was 4.3 times at June 30 against a 4.25 times limit for the second half. If the second half cash flow disappoints, ACCO would need lender consent or equity support, and the shareholders pay for both. - **Refinancing.** $575 million of 4.25% notes must be refinanced by September 2028. At 8.5% the extra cost is about $0.19 a share after tax, 21% of 2026 adjusted earnings per share (my estimate). - **Shrinking sales.** Net sales are down 21.7% since 2022 and International comparable sales fell about 9% in the second quarter. Technology accessories are softening as enterprise buyers shift budget to AI. - **Margin squeeze.** Management expects second half gross and operating margins below last year, because inflation and tariffs arrive before price increases. - **Earnings quality.** The $36.5 million bargain purchase gain is larger than first half GAAP net income of $33.5 million, and restructuring is added back every year. Counting it as a recurring cost lowers my Base to $3.97. - **Pension and dilution.** Noncurrent pension obligations were $108.4 million at June 30, ACCO also sits in a union multi-employer plan that is in critical and declining status (contributions are described as not significant), and the share count rose 2.4% between March and July. ## Management execution Thomas Tedford has been chief executive since 2023, and the record since then is mixed in a specific way. The cost program is delivering, guidance was raised in July, and EPOS was a smart small deal. Against that, sales are still shrinking, debt peaked above 4 times, International leadership changed in 2026 and the pipeline of acquisitions is described as attractive while the leverage covenant tightens. Dividends were kept at $0.30 and buybacks stopped. **Assessment: 11/20, executing on cost, still searching for sales.** ## Stock Analyza scorecard | Economic classification (non-financial scorecard) | Score | | --- | --- | | Return on capital above the cost of capital | 0/2 | | Growth | 0/2 | | Per-share growth | 0/2 | | Capital strength | 0/1 | | Scalability | 0/1 | | Recurring economics | 1/2 | | Reinvestment runway at high returns | 0/2 | | Total: Standard | 1/12 | Adjusted return on invested capital is about 7.2% (my calculation: adjusted operating income after a 26.7% tax rate, over equity plus net debt plus pension), no better than a cost of capital that I put near 8%, so the return point is zero. Sales and per-share earnings are down over three years, which takes growth, per-share growth and runway to zero. Leverage of 4.3 times takes the capital point. Everyday school and office products are bought repeatedly but not under contract, so recurring economics get 1 point. At 1 of 12 the business is Standard, far from the Quality Growth line. Character change: changing, because small acquisitions are meant to replace lost organic sales. That is neutral for now and would be negative if they were financed with more debt. Business quality is **38/100**: moat and pricing power 8/20, return versus cost of capital 5/20, balance sheet and resilience 5/15, earnings quality 8/15, growth and runway 3/15, management and capital allocation 6/10, dilution and governance 3/5. The valuation score is **32/100**: discount to Base 11/40, protection against the Bear case 2/20, agreement between methods 10/15, position in the 52 week range as a weak history proxy 2/10, market-implied expectations 5/10, data and model quality 2/5. ## Confidence score | Confidence | Score | | --- | --- | | Data quality / source provenance | 4/5 | | Predictability | 2/5 | | Valuation robustness | 2/5 | | Accounting transparency | 3/5 | | Scenario dispersion | 2/5 | | Total | 13/25, grade C | Headline numbers come from the company's own releases and the 10-Q and 10-K, which is why data quality scores 4. Predictability is low for a shrinking business with an unquantified tariff exposure. Valuation robustness is low because the share value is so sensitive to the multiple: each turn is worth 41% of the price. Scenario dispersion is wide, with values from $1.93 to $8.36. ## What I would watch from here ### Green - Full year adjusted EPS of $0.87 or more and third quarter adjusted EPS of $0.17 or more - Year end leverage ratio of 3.9 times or lower - Free cash flow for 2026 of $75 million or more - Comparable sales decline narrower than 3%, with International comparable sales improving ### Yellow - Full year adjusted EPS of $0.80 to $0.87 - Year end leverage of 3.9 to 4.25 times - Free cash flow of $55 million to $75 million - Comparable sales down 3% to 6% ### Red - Full year adjusted EPS below $0.80 - Leverage above 4.25 times at any quarter end in the second half, or a covenant amendment - Free cash flow below $55 million - Comparable sales down more than 6%, or a dividend cut Today's readings: leverage is **red today** at 4.3 times against the 4.25 times second half limit, though that is the seasonal peak and management guides to 3.7 to 3.9 times at year end. Guidance for adjusted EPS ($0.87 to $0.91) and free cash flow ($75 million to $85 million) is green. Comparable sales (down 2.5% in the first half) are green, with International (down about 9% in the second quarter) the weak spot. The next review point is the third quarter report, expected on October 29, 2026. ## The three most important thesis breakers 1. Leverage fails to fall below 4.25 times in the second half, or the lenders have to amend the covenant. 2. Normalized EBITDA after stock pay slides toward $155 million because sales decline faster and price increases do not cover inflation and tariffs. 3. The 2029 notes can only be refinanced at a far higher rate, or the dividend is cut to protect the covenant. ## Stress test and independent check I recomputed every table in a separate script: the equity bridge, the sensitivity grid, the free cash flow method, the triangulation, the reverse valuation, the scenario bridges from sales and margin, the dividend arithmetic and the margin of safety. Reported inputs come from the second quarter release, the June 30 10-Q, the 2025 results and the 2025 10-K, and the price is the close shown by a market data aggregator for October 12, 2026. | Robustness check (Base case) | Triangulated value | Versus $4.54 | | --- | --- | --- | | Triangulated Base | $4.94 | +8.8% | | Net debt at June 30 ($827.4 million) instead of the two date average | $4.78 | +5.3% | | Net debt at December 31 ($776.5 million) | $5.10 | +12.3% | | Unfunded pension obligations after tax added to debt | $4.43 | -2.4% | | Outstanding (92.3 million) instead of diluted shares | $5.12 | +12.7% | | EBITDA before stock pay ($191 million) | $5.55 | +22.4% | | EBITDA 10% lower ($159 million) | $4.16 | -8.3% | | Restructuring treated as a recurring cost (EBITDA $155 million) | $3.97 | -12.5% | | Multiple 6x and 8x on both methods | $3.51 and $6.36 | -22.6% and +40.2% | | Notes refinanced at 8.5% (free cash flow $57 million) | $4.42 | -2.7% | | Tariff refund of $25 million received in cash | $5.06 | +11.4% | | Equal weight of the two methods | $5.03 | +10.8% | | Most generous: $191 million, 8x, outstanding shares | $7.32 | +61.2% | | Harshest: $159 million, 6x, June debt, pension in debt | $2.18 | -52.0% | Changes to net debt, share count, tariffs or the weighting of the methods move the value by 13% or less, which is why this is a hold and not a reduce or a buy. What moves it further is the multiple (6 times gives $3.51, 8 times gives $6.36) and the EBITDA definition (before stock pay the value is $5.55). Treating restructuring as a recurring cost takes the Base to $3.97, and the harshest combination gives $2.18, 52% below the price. The strongest counter-thesis, for the bulls: the stock is at 5.1 times earnings, free cash flow guidance equals 18% of the market value, guidance was just raised, and every $80 million of debt repaid belongs to the shareholders. If cash flow lands at $85 million and the multiple moves to 8 times, the value is about $6.70. The response is the covenant, the 2029 refinancing and sales that have fallen three years in a row, all of which sit between the shareholders and that cash. Main data limits: peer multiples and ACCO's own multiple history on this basis were not available to me, the 7.0 times multiples and the normalized cash flow are my estimates, the second half cash flow split is a guess based on guidance, and the 8.5% refinancing rate is an assumption. ## Final verdict: hold at $4.54 ACCO is a cash-generative owner of real brands that the market has stopped writing off, and the price already reflects that. What the price does not reflect is how little room $802 million of net debt leaves. A small miss in EBITDA or a turn lost in the multiple removes a large part of the equity, while a small beat adds as much. **Verdict: HOLD at $4.54, watchlist for new money. Triangulated Base value $4.94, upside 8.8%, Confidence C (13/25), required margin of safety 45%, maximum buy price $2.72.** The main risk to this verdict is a second half in which leverage stays above 4.25 times, because then the question stops being valuation and becomes who owns the cash. ## More analyses on Patreon This analysis is free. Premium members get every in-depth analysis, the full archive and a vote on which stocks get analyzed next: https://www.patreon.com/stockanalyza ## Sources Primary sources include ACCO Brands' [second quarter 2026 results release](https://ir.accobrands.com/news/news-details/2026/ACCO-Brands-Reports-Second-Quarter-Results/default.aspx) of July 30, 2026, the [10-Q for the period ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/712034/000119312526328057/acco-20260630.htm), the [fourth quarter and full year 2025 results](https://www.sec.gov/Archives/edgar/data/712034/000119312526097823/acco-ex99_1.htm), the [2025 Form 10-K](https://www.sec.gov/Archives/edgar/data/712034/000119312526098616/acco-20251231.htm) and the [full year 2023 results](https://www.sec.gov/Archives/edgar/data/712034/000095017024018799/acco-ex99_1.htm). Management commentary on guidance, EPOS, tariff refunds and the second half comes from the [second quarter 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/08/07/acco-acco-q2-2026-earnings-call-transcript/). Market price history comes from a [third-party market data aggregator](https://stockanalysis.com/stocks/acco/history/). Broker price targets and ratings are not used. The reference market price is $4.54, the regular session close on October 12, 2026. Balance sheet figures are as of June 30, 2026 and December 31, 2025, averaged as described above. Values per share use 95.6 million diluted shares. Normalized EBITDA, normalized free cash flow, multiples, scenario values and robustness tests are analytical estimates, not company guidance. **Disclaimer.** This analysis is provided solely for research and educational purposes. It is not personalized investment, financial, legal or tax advice. Values are estimates, not forecasts or trading instructions. ACCO is exposed to declining demand for its products, tariffs and input costs, high leverage and refinancing risk, and the dividend is not guaranteed. Investors can lose part or all of their invested capital. Method: Master Investment Analysis Framework v3.3. Approach: enterprise value to normalized EBITDA after stock pay, with a price to normalized free cash flow cross-check. Confidence: C/13. Data checks: passed with warnings. Open data gaps: peer multiples, the company's own multiple history and the second half cash flow split.